英文药名: Zalutia(Tadalafil Tablets) 中文药名: 他达拉非片 生产厂家: 武田药品 药品介绍： 他达拉非是环磷酸鸟苷(cGMP)特异性磷酸二酯酶5(PDE5)的选择性、可逆性抑制剂。 体外研究表明他达拉非是一种选择性PDE5抑制剂，PDE5存在于海绵体平滑肌、前列腺、膀胱、血管、内脏平滑肌、骨骼肌、血小板、肾、肺、小脑和胰脏中。他达拉非与PDE5的作用要强于其它磷酸二酯酶。 他达拉非于口服后快速吸收，服药后中位时间2小时达到平均最大观测血浆浓度(Cmax)。口服本品后的绝对生物利用度尚未明确。他达拉非的吸收率和程度不受食物的影响，所以本品可以与或不与食物同服。服药时间(早晨或晚上)对吸收率和程度没有临床意义的影响。 药理作用特点： 他达拉非口服经胃肠道吸收后，能在30分钟内起效，且疗效持续36小时，是目前仅有的三种ED药物中起效快，药效持续时间最长，且唯一不受高脂饮食和酒精摄入影响的药物。西地那非和伐地那非药效持续时间不超过4小时，酒精和高脂饮食均影响药效的发挥。 适应症： 良性前列腺增生有关的排尿障碍 剂量和用法 每天一次，每次5毫克 ------------------------------------------------------- 注：以下产品不同规格和不同价格，购买以咨询为准！ ------------------------------------------------------- 产地国家: 日本 原产地英文商品名: Zalutia（ザルティア錠）2.5mg  100Tablets 原产地英文药品名: Tadalafil 中文参考商品译名: Zalutia（ザルティア錠）2.5毫克 100片/盒 中文参考药品译名: 他达拉非 生产厂家中文参考译名: 武田药品 生产厂家英文名: Takeda Pharmaceutical ------------------------------------------------------- 产地国家: 日本 原产地英文商品名: Zalutia（ザルティア錠）5mg  100Tablets 原产地英文药品名: Tadalafil 中文参考商品译名: Zalutia（ザルティア錠）5毫克 100片/盒 中文参考药品译名: 他达拉非 生产厂家中文参考译名: 武田药品 生产厂家英文名: Takeda Pharmaceutical Nippon Shinyaku launches “Zalutia® tablets 2.5mg” and “Zalutia® tablets 5mg” for urinary disorder caused by benign prostatic hyperplasia Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan, President: Shigenobu Maekawa) today announced the launch of “Zalutia® tablets 2.5mg” and “Zalutia® tablets 5mg” (generic name: tadalafil) for urinary disorder caused by benign prostatic hyperplasia (BPH). Zalutia® is a medication with a new mechanism of action (phosphodiesterase 5 inhibitor) for the treatment of urinary disorder caused by BPH developed by Eli Lilly Japan K.K. (Headquarters: Kobe, Japan; President: Patrik Jonsson). Eli Lilly Japan K.K. submitted a New Drug Application in February 2013 and received the marketing authorization in January 2014. Urinary disorder caused by BPH is a condition which makes urination difficult mainly due to hyperplasia of prostatic cells (internal gland) that often occurs with aging. The disorder affects men 50 years of age or older and a variety of symptoms are observed such as “a weak stream when urinating”, ”difficulty empting the bladder” or “frequent urination during the day or night”. This medication is expected to improve lower urinary tract symptoms of BPH through its phosphodiesterase 5 inhibiting effect, and is considered to improve blood flow by relaxing vascular smooth muscle, enhancing the relaxing activity of the urethra, prostate and bladder neck, and inhibiting the activity of afferent neurons in the bladder. Urology is a priority area for Nippon Shinyaku, and through the launch of this medication, we hope to contribute to the improvement of patients’ QOL by providing the clinical settings with a new treatment option for urinary disorder caused by BPH.